Clinical and economic analysis of pharmacotherapy of patients with chronic pancreatitis in the Druzhkovka healthcare institution




chronic pancreatitis, clinical and economic analysis, ABC- analysis, VEN-analysis, frequency analysis


Aim. To determine the pharmacotherapy compliance of patients with chronic pancreatitis (CP) to medical and technological documents using clinical and economic analysis.

Materials and methods. 94 case histories of patients with CP from the age of 25 to 65 who were treated at the therapeutic department of one of the Druzhkovka healthcare institutions (HCI) were analyzed. The research period was within 2015-2017. The clinical and economic analysis of pharmacotherapy of these patients was performed using ABC, VEN and frequency analyses.

Results and discussion. It was determined that the majority of prescribed medicines were recommended by clinical protocols for use in the pharmacotherapy of the main CP and concomitant diseases diagnosed in the patients studied. These medicines are present in the State Formulary of Ukraine (SFU) (80.25 % and 91.36 %, respectively). The medicines that were present in the above documents were prescribed in most cases of all medical indications (67.50 % and 94.72 %, respectively). Most of the costs related to pharmacotherapy of patients with CP were spent on these medicines (60.00 % and 87.17 %, respectively).

Conclusions and prospects of further research. Comparison of the results of ABC-, VEN- and frequency analyses showed that the main directions of pharmacotherapy of patients with CP in the therapeutic department of one of the Druzhkovka HCI corresponded to the clinical protocols of medical care for patients with CP and concomitant diseases at the time of the study, and the choice of trademarks of medicines was carried out, preferably, in accordance with the SFU. However, a significant number of medical prescriptions and a considerable part of the costs were related to the secondary drugs, which were absent in clinical protocols (32.50 % of prescriptions and 40.00 % of costs, respectively). Therefore, in general, the real pharmacotherapy of patients with CP in the therapeutic department of one of the Druzhkovka HCI is not rational from the clinical and economical point of view and needs further correction in accordance with the given medicotechnological documents. Optimization of pharmacotherapy of patients with CP in this department and money for its implementation are possible due to the exclusion of Solcoseril, a drug affecting the digestive system and metabolic processes, which is expensive and absent in clinical protocols and the SFU, from the treatment regimens. It was prescribed in 0.83% of all cases, and 5.70% of the total cost of medicines was spent on it.

Author Biographies

L. V. Iakovlieva, National University of Pharmacy

Honored Worker of Science and Technology of Ukraine, Doctor of Pharmacy (Dr. habil), professor, head of the Department of Pharmacoeconomics

O. O. Gerasymova, National University of Pharmacy

Candidate of Pharmacy (Ph. D), associate professor of the Department of Pharmacoeconomics

S. S. Shershnova, National University of Pharmacy

Student of the specialty “Clinical Pharmacy”

N. O. Matiashova, National University of Pharmacy

Candidate of Pharmacy (Ph. D), teaching assistant of the Department of Pharmacoeconomics


Babinets, L. S. (2012). Zdorov’ia Ukrainy, 1 (23), 61–63.

Mihenko, B. O. (2015). Visnyk naukovykh doslidzhen, 3, 11–14.

Rusyn, V. I., Sirchak, Ye. S., Kurchak, N. Yu. (2013). Hastroenterolohiia, 3 (49), 123–126.

Lévy, P., Domínguez-Muñoz, E., Imrie, C., Löhr, M., & Maisonneuve, P. (2014). Epidemiology of chronic pancreatitis: burden of the disease and consequences. United European Gastroenterology Journal, 2 (5), 345–354.

Morales, M. J. (2017). Chronic Pancreatitis: Current Concepts. SM Pancreat Disord Ther., 1 (1), 1001.

Halloran, Christopher. (2009). Vnutrenniaia meditcina, 4 (16). Available at :

Mitish, V. A., Mahkamova, F. T., Paskhalova, Yu. S., Gruzman, V. A., Margolina, I. I. & Sokov, S. L. (2015). Hirurgija. Zhurnal imeni N. I. Pirogova - Surgery. Journal named after N. I. Pirogov, 4, 48–53.

Yakovlieva, L. V., Herasymova, О. О., Horbachova, А. S. & Krasiuk, А. А. (2015). Farmatsevtychnyi chasopys, 3, 83–87.

Kotvitska, А. А. & Kononenko, O. V. (2015). Farmatsevtychnyi zhurnal, 6, 3–9.

Nemchenko, A., Nazarkina, V., & Kurylenko, Y. (2018). The study of the state of pharmaceutical provision for patients with cardiovascular diseases using ABC- and VEN-analyses. Vìsnik farmacìï, 3 (95), 44–48.

Morozov, A. M., Yakovlieva, L. V., Bezditko, N. V., Mishchenko, O. Ya., Stepanenko, A. V., Zimenkovskyi, A. B. (2013). Otsinka klinichnoi ta ekonomichnoi dotsilnosti vykorystannia likarskykh zasobiv u likuvalno-profilaktychnomu zakladi (suprovid formuliarnoi systemy) : metodychni rekomendatsii. Kharkiv : Styl-Yzdat, 36.

12. Derzhavnyi formuliar likarskykh zasobiv Ukrainy. (n.d.). Available at :

13. Poshukova systema Reiestr medyko-tekhnolohichnykh dokumentiv. (n.d.). Available at :

Kompendyum OnLine: dovidnyk. (n.d.). Available a t:

15. Nakaz MOZ Ukrainy № 918 vid 28.10.2010 r. “Pro zatverdzhennia metodychnykh rekomendatsii shchodo monitorynhu ta otsinky diievosti formuliarnoi systemy na etapi yii vprovadzhennia”. (2010). Available at :

Alhorytm dii likaria pry nadanni medychnoi dopomohy patsiientam iz khronichnym pankreatytom. (2014). Ukrainskyi medychnyi chasopys, 6 (104), 154–159.

Zviahyntseva, T. D. & Sharhorod, I. I. (2015). East European Journal of Internal and Family Medicine, 1,10–16.





Experimental and Clinical Pharmacology